About Y-mAbs Therapeutics, Inc.

Y-mAbs is a clinical-stage biopharmaceutical company developing antibody immunotherapies targeting rare pediatric cancers, including neuroblastoma and osteosarcoma. Their treatments aim to improve survival rates and safety for patients facing these challenging conditions through ongoing clinical trials.

```xml <problem> Rare pediatric cancers like neuroblastoma, osteosarcoma, and diffuse intrinsic pontine glioma (DIPG) present significant treatment challenges, often with limited effective and targeted therapeutic options available. These cancers can be aggressive and difficult to treat, leading to poor outcomes and safety concerns for young patients. </problem> <solution> Y-mAbs Therapeutics is a biopharmaceutical company focused on developing antibody immunotherapies for treating rare pediatric cancers. Their approach involves targeting specific antigens present in cancer cells to stimulate an immune response and neutralize the disease. Through ongoing clinical trials, Y-mAbs is investigating innovative antibody-based products with the goal of improving survival rates and safety profiles for children facing neuroblastoma, osteosarcoma, and other challenging cancers. Their research and development efforts are centered on creating targeted therapies that can extend survival and address the unique needs of pediatric oncology patients. </solution> <features> - Development of antibody immunotherapies designed to target specific antigens on cancer cells. - Focus on rare pediatric cancers, including neuroblastoma, osteosarcoma, diffuse intrinsic pontine glioma (DIPG), and medulloblastoma. - Clinical trials evaluating the safety and efficacy of novel antibody-based treatments. - Investigating treatments for Central Nervous System (CNS)/Leptomeningeal Metastases (LM) resulting from cancers like neuroblastoma. </features> <target_audience> The primary target audience includes pediatric oncology patients, their families, and medical professionals specializing in the treatment of rare and aggressive childhood cancers. </target_audience> ```

What does Y-mAbs Therapeutics, Inc. do?

When was Y-mAbs Therapeutics, Inc. founded?

Y-mAbs Therapeutics, Inc. was founded in 2015.

How much funding has Y-mAbs Therapeutics, Inc. raised?

Y-mAbs Therapeutics, Inc. has raised 115000000.

Founded

2015

Funding

115000000

Employees

113 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Y-mAbs Therapeutics, Inc.

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

ymabs.com 7K+

Crunchbase

Founded 2015

Funding

Estimated Funding

$100M+

Team (100+)

No team information available.

Company Description

Problem

Rare pediatric cancers like neuroblastoma, osteosarcoma, and diffuse intrinsic pontine glioma (DIPG) present significant treatment challenges, often with limited effective and targeted therapeutic options available. These cancers can be aggressive and difficult to treat, leading to poor outcomes and safety concerns for young patients.

Solution

Y-mAbs Therapeutics is a biopharmaceutical company focused on developing antibody immunotherapies for treating rare pediatric cancers. Their approach involves targeting specific antigens present in cancer cells to stimulate an immune response and neutralize the disease. Through ongoing clinical trials, Y-mAbs is investigating innovative antibody-based products with the goal of improving survival rates and safety profiles for children facing neuroblastoma, osteosarcoma, and other challenging cancers. Their research and development efforts are centered on creating targeted therapies that can extend survival and address the unique needs of pediatric oncology patients.

Features

Development of antibody immunotherapies designed to target specific antigens on cancer cells.

Focus on rare pediatric cancers, including neuroblastoma, osteosarcoma, diffuse intrinsic pontine glioma (DIPG), and medulloblastoma.

Clinical trials evaluating the safety and efficacy of novel antibody-based treatments.

Investigating treatments for Central Nervous System (CNS)/Leptomeningeal Metastases (LM) resulting from cancers like neuroblastoma.

Target Audience

The primary target audience includes pediatric oncology patients, their families, and medical professionals specializing in the treatment of rare and aggressive childhood cancers.